Intestinal Pseudo-obstruction Treatment Market - Top Companies and Manufacturers

Companies Dominating the Intestinal Pseudo-obstruction Treatment Market

GlaxoSmithKline Plc.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Abbott Laboratories
Pfizer Inc.
Johnson & Johnson
Callisto Pharmaceuticals Inc.
Biogen Inc.
Novartis A.G
Canila Healthcare Ltd
AbbVie Inc.
Eli Lilly and Company

Browse Key Market Insights with Data Illustration:

Intestinal Pseudo-obstruction Treatment Market Forecast Report 2037

In the News

GSK Plc. declared that it has fulfilled the acquirement of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical organization concentrated on tackling the unmet treatment requirements of patients with respiratory and inflammatory situations.

GSK Plc. declared that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved for review the regulatory application of Shingrix for the prohibition of shingles (herpes zoster) in adults aged 18 years and more than at growing risk.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of intestinal pseudo-obstruction treatment is evaluated at USD 25.32 billion.

The intestinal pseudo-obstruction treatment market size was valued at USD 24.33 billion in 2024 and is set to exceed USD 46.45 billion by 2037, expanding at over 5.1% CAGR during the forecast period i.e., between 2025-2037. The increased frequency of gastrointestinal disease will drive the market growth.

North America industry is anticipated to account for largest revenue share of 45% by 2037, owing to increasing advancement in the tools of diagnosis in this region.

The major players in the market are GlaxoSmithKline Plc., Abbott Laboratories, Pfizer Inc., Johnson & Johnson, Callisto Pharmaceuticals Inc., Biogen Inc., Novartis A.G., Canila Healthcare Ltd, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Co Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co Ltd.

Intestinal Pseudo-obstruction Treatment Market - Top Companies and Manufacturers

Companies Dominating the Intestinal Pseudo-obstruction Treatment Market

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the intestinal pseudo-obstruction treatment market?

What are the factors driving the intestinal pseudo-obstruction treatment landscape?

Which region held the largest intestinal pseudo-obstruction treatment industry share?

Who are the key players in the intestinal pseudo-obstruction treatment sector?